Skip to main content
Daily Report

Daily Cardiology Research Analysis

01/24/2025
3 papers selected
3 analyzed

Three studies reshape cardiovascular risk assessment and procedural quality: (1) a life-course analysis shows polygenic risk scores (PRS) add the most value for predicting coronary artery disease at younger ages; (2) intravascular imaging (IVI) use in PCI has rapidly increased and demonstrates high reliability as a performance measure; and (3) coronary CT plaque composition (non-calcified burden) independently predicts long-term MACE beyond stenosis extent. Together, these findings support preci

Summary

Three studies reshape cardiovascular risk assessment and procedural quality: (1) a life-course analysis shows polygenic risk scores (PRS) add the most value for predicting coronary artery disease at younger ages; (2) intravascular imaging (IVI) use in PCI has rapidly increased and demonstrates high reliability as a performance measure; and (3) coronary CT plaque composition (non-calcified burden) independently predicts long-term MACE beyond stenosis extent. Together, these findings support precision prevention, quality benchmarking, and refined imaging-based prognosis.

Research Themes

  • Precision cardiovascular risk prediction with genomics across the life course
  • Quality measurement and performance metrics in interventional cardiology
  • Imaging-based plaque characterization for long-term prognosis

Selected Articles

1. Dynamic Importance of Genomic and Clinical Risk for Coronary Artery Disease Over the Life Course.

81Level IICohort
Circulation. Genomic and precision medicine · 2025PMID: 39851049

Across two large longitudinal cohorts (FOS and UK Biobank), CAD polygenic risk had its greatest predictive value at younger ages, outperforming pooled cohort equations especially in the 40–45 age group. Adding PRS increased AUC overall by 5.1% and by 6.5% in individuals under 55, supporting age-tailored precision prevention.

Impact: This study operationalizes when genomic risk adds the most value, directly informing timing of risk stratification and preventive therapy initiation. It supports integrating PRS into earlier-life screening pathways.

Clinical Implications: Consider incorporating PRS for CAD risk assessment in adults under 55 to identify high-risk individuals earlier than traditional models, enabling earlier statin/lifestyle interventions and targeted follow-up.

Key Findings

  • CAD PRS hazard ratio was 3.58 at age 19 (FOS) and 1.51 by age 70 (UKB), indicating age-dependent diminishing effect.
  • In ages 40–45, PRS identified 3.2-fold more subsequent CAD events than pooled cohort equations.
  • Adding PRS improved AUC by +5.1% overall and by +6.5% in individuals <55 years.

Methodological Strengths

  • Large, well-characterized longitudinal cohorts (FOS and UK Biobank) with extensive person-time.
  • Age-stratified hazard modeling and comparative prediction against established pooled cohort equations.

Limitations

  • Observational design limits causal inference and may be influenced by unmeasured confounding.
  • Predominantly European ancestry may limit generalizability to other populations.

Future Directions: Prospective implementation studies to test PRS-guided prevention pathways, evaluation in diverse ancestries, and cost-effectiveness analyses for earlier-life screening.

BACKGROUND: Earlier identification of high coronary artery disease (CAD) risk individuals may enable more effective prevention strategies. However, existing 10-year risk frameworks are ineffective at earlier identification. We sought to understand how the variable importance of genomic and clinical factors across life stages may significantly improve lifelong CAD event prediction. METHODS: A longitudinal study was performed using data from 2 cohort studies: the FOS (Framingham Offspring Study) with 3588 participants aged 19 to 57 years and the UKB (UK Biobank) with 327 837 participants aged 40 years to 70 years. A total of 134 765 and 3 831 734 person-time years were observed in FOS and UKB, respectively. Hazard ratios for CAD were calculated for polygenic risk score (PRS) and clinical risk factors at each age of enrollment. The relative importance of PRS and pooled cohort equations in predicting CAD events was also evaluated by age groups. RESULTS: The importance of CAD PRS diminished over the life course, with a hazard ratio of 3.58 (95% CI, 1.39-9.19) at the age of 19 years in FOS and a hazard ratio of 1.51 (95% CI, 1.48-1.54) by the age of 70 years in UKB. Clinical risk factors exhibited similar age-dependent trends. PRS significantly outperformed pooled cohort equations in identifying subsequent CAD events in the 40- to 45-year age group, with 3.2-fold more appropriately identified events. Overall, adding PRS improved the area under the receiving operating curve of the pooled cohort equations by an average of +5.1% (95% CI, 4.9%-5.2%) across all age groups; among individuals <55 years, PRS augmented the area under the receiver operater curve (ROC) of the pooled cohort equations by 6.5% (95% CI, 5.5%-7.5%; CONCLUSIONS: Genomic and clinical risk factors for CAD display time-varying importance across the lifespan. The study underscores the added value of CAD PRS, particularly among individuals younger than 55 years, for enhancing early risk prediction and prevention strategies. All results are available at https://surbut.github.io/dynamicHRpaper/index.html.

2. Intravascular Imaging as a Performance Measure for Percutaneous Coronary Intervention.

76Level IIICohort
Circulation. Cardiovascular interventions · 2025PMID: 39851056

In a 136,071-PCI VA cohort, IVI use rose from 12.3% to 43.1% (2010–2022) with high reliability (>0.96) as a hospital/physician-level performance measure. Variability was driven mainly by hospitals and operators, supporting national measurement and reporting; no 1-year mortality/MACE differences were observed in the contemporary cohort.

Impact: Establishes IVI as a reliable pass/fail performance metric and quantifies provider-level variability, enabling quality improvement and policy adoption in PCI programs.

Clinical Implications: Health systems can measure and report IVI use as a quality metric, target hospital/operator variability with training, and encourage broader adoption in complex lesions (CTO, LM).

Key Findings

  • IVI use increased from 12.3% (2010) to 43.1% (2022) across 136,071 PCI procedures.
  • Usage variability was largely attributable to hospital (54%) and physician (33%) levels.
  • Reliability of IVI as a pass/fail performance measure exceeded 0.96 at both hospital and physician levels.
  • No significant association with 1-year mortality or MACE was observed in the contemporary cohort.

Methodological Strengths

  • Large national dataset with temporal trends and provider-level variance decomposition.
  • Robust reliability testing and 1-year outcome assessment using mixed and Cox models.

Limitations

  • Observational retrospective design; potential residual confounding.
  • Findings from VA hospitals may limit generalizability to non-VA settings.

Future Directions: Evaluate patient-centered outcomes under IVI-based quality programs, define optimal use thresholds, and link IVI adoption to technical success and long-term outcomes.

BACKGROUND: Intravascular imaging (IVI) is widely recognized to improve outcomes after percutaneous coronary intervention (PCI). However, IVI is underutilized and is not yet established as a performance measure for quality PCI. METHODS: We examined temporal trends of IVI use for all PCIs performed at Veterans Affairs hospitals in the United States from 2010 to 2022 using retrospective observational cohorts. IVI was defined as intravascular ultrasound or optical coherence tomography. A contemporary subset of PCIs from 2020 to 2022 was used to examine clinical characteristics associated with IVI use and test the reliability of IVI as a pass/fail performance measure. We then used a generalized linear mixed model to estimate the proportion of IVI use variability attributable to the hospital, physician, and patient level. Cox proportional hazard models were used to assess the association of IVI with clinical outcomes at 1 year. RESULTS: IVI use increased from 12.3% in 2010 to 43.1% in 2022 in 136 071 PCIs included in the study. Among 22 918 PCIs in the contemporary cohort, IVI was more frequent with nonemergent presentations, chronic total occlusions, and left main lesions but usage variability was primarily attributable to hospital (54%) and physician (33%) levels. As a pass/fail performance measure, reliability was high (>0.96) at hospital and physician levels. However, IVI use was not associated with statistically significant differences in mortality or major adverse cardiovascular events in this cohort. CONCLUSIONS: IVI use for PCI is increasing rapidly at Veterans Affairs hospitals in the United States but with marked variation at the hospital and physician levels. IVI meets established criteria for an effective performance measure and should be measured and reported by local and national organizations to encourage further uptake. Ongoing training and quality improvement may be required to maximize the benefit of IVI as it is more widely utilized.

3. Prognostic value of coronary plaque composition in symptomatic patients with obstructive coronary artery disease.

74Level IICohort
European radiology · 2025PMID: 39853336

In a 2,312-patient multicenter registry (median 6.7 years), the number of segments with non-calcified plaque independently predicted MACE beyond traditional risk factors and CAD burden. Adding plaque composition improved discrimination (ΔC-statistic +0.03) and reclassification (NRI 28.6%, IDI 5.4%).

Impact: Demonstrates that plaque composition, especially non-calcified burden, refines long-term risk beyond stenosis extent, informing imaging-based risk stratification and preventive targeting.

Clinical Implications: CCTA reporting should incorporate non-calcified plaque burden for symptomatic obstructive CAD to guide intensified prevention (lipid lowering, anti-inflammatory strategies) beyond stenosis-centric decisions.

Key Findings

  • Non-calcified plaque segment count independently associated with MACE (p<0.001) over 6.7-year median follow-up.
  • Adding plaque composition to clinical + CAD burden models improved C-statistic by 0.03 and yielded NRI 28.6% and IDI 5.4%.
  • Proximal ≥50% stenosis segments and number of obstructive vessels also independently predicted MACE.

Methodological Strengths

  • Large multicenter registry with long median follow-up and adjudicated MACE.
  • Sequential multivariable modeling to quantify incremental prognostic value.

Limitations

  • Visual plaque classification may introduce observer variability.
  • Registry design limits control over therapy changes and residual confounding.

Future Directions: Standardize quantitative plaque composition metrics and test whether targeting non-calcified plaque burden improves hard outcomes in prospective trials.

OBJECTIVES: To determine whether plaque composition analysis defined by cardiac CT can provide incremental prognostic value above coronary artery disease (CAD) burden markers in symptomatic patients with obstructive CAD. MATERIALS AND METHODS: Between 2009 and 2019, a multicentric registry included all consecutive symptomatic patients with obstructive CAD (at least one ≥ 50% stenosis on CCTA) and was followed for major adverse cardiovascular (MACE) defined by cardiovascular death or nonfatal myocardial infarction. Each coronary segment was scored visually for both the degree of stenosis and composition of plaque, which were classified as non-calcified, mixed, or calcified. To assess the prognostic value of each CCTA findings, different multivariable Cox regression models were used: model 1: clinical (traditional risk factors); model 2: model 1 + CAD burden (number of proximal segments with stenosis ≥ 50% + number of vessels with obstructive CAD); and model 3: model 2 + plaques feature (number of segments with non-calcified plaque). RESULTS: Of 2312 patients (mean age 70 ± 12 years, 46% men), 319 experienced a MACE (13.8%) (median follow-up: 6.7 years (5.9-9.1)). The number of proximal segments with ≥ 50% stenosis, the number of vessels with obstructive CAD, and the number of segments with non-calcified plaque were all independently associated with MACEs (all p < 0.001). The addition of plaque composition analysis (model 3) showed the best improvement in model discrimination and reclassification (C-statistic improvement = 0.03; net reclassification improvement = 28.6%; integrative discrimination index = 5.4%, all p < 0.001). CONCLUSIONS: In this population, the analysis of coronary plaque composition had an incremental prognostic value to predict MACEs above a model combining traditional risk factors and CAD burden. KEY POINTS: Question Several coronary computed tomography angiography (CCTA) studies have shown the potential interest of plaque composition analysis, which can be further evaluated. Findings In symptomatic patients with obstructive coronary artery disease (CAD), plaque composition analysis had an incremental prognostic value above a model combining traditional risk factors and CAD burden. Clinical relevance In symptomatic patients with obstructive CAD, plaque composition analysis using CCTA has a strong incremental prognostic value above a model combining traditional risk factors and CAD burden, thus translating into a more accurate long-term major adverse cardiovascular event prediction.